Doptelet 
Safety Profile

Learn about the possible side effects of Doptelet® (avatrombopag).

Doptelet Platelet Characters in the Woods at Sunset

Doptelet has an established safety profile1,2

Adverse reactions with a frequency ≥10% in adults with chronic ITP treated with Doptelet—
pooled data from clinical trials.1*

Adverse ReactionDoptelet
(N=128)
%		Placebo
(N=22)
%
Headache3114
Fatigue289
Contusion2618
Epistaxis1918
Upper Respiratory Tract Infection155
Arthralgia130
Gingival Bleeding130
Petechiae119
Nasopharyngitis100

Doptelet has no reported interactions with statins, no cataracts precautions, and no associated liver damage.1,3†

*The American Society of Hematology (ASH) guidelines define a durable response as platelet count ≥30x109/L and at least doubling of the baseline count at 6 months.4

†Doptelet had no significant liver damage reported in clinical trials. Therefore, no additional liver function monitoring is required.2

Doptelet Safety and Tolerability

Thrombotic/Thromboembolic Complications1

  • In clinical trials in patients with chronic ITP, 7% (9/128) of patients treated with Doptelet developed a thromboembolic event

Serious Adverse Reactions1,2

  • Serious adverse reactions that occurred more frequently in patients with chronic ITP treated with Doptelet (9%; 12/128) compared to placebo (5%; 1/22) included headache, occurring in 1.6% (2/128)

  • Adverse reactions resulting in discontinuation of Doptelet that were reported in more than 1 patient included headache, occurring in 1.6% (2/128)

Doptelet Platelet Characters Having a Picnic

Discover Doptelet dosing

Learn how to titrate Doptelet with our titration calculator.

VIEW DOSING

Drug Interactions

Dose adjustments are recommended for patients with chronic immune thrombocytopenia taking moderate or strong dual CYP2C9 and CYP3A4 inducers or inhibitors.

  1. DOPTELET (avatrombopag) [prescribing information]. Durham, NC: AkaRx, Inc; 2021.
  2. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479-490. 
  3. DOPTELET (avatrombopag) [patient information leaflet]. Durham, NC: AkaRx, Inc; 2021.
  4. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.